<DOC>
	<DOCNO>NCT01177813</DOCNO>
	<brief_summary>The aim study investigate efficacy , safety tolerability BI 10773 compare placebo sitagliptin give 24 week monotherapy patient T2DM insufficient glycaemic control . For open-label part study objective estimate efficacy safety BI 10773 give 24 week patient T2DM poor glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety Empagliflozin ( BI 10773 ) Versus Placebo Sitagliptin Over 24 Weeks Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent ; 2 . Male female patient diet exercise regimen drugna√Øve ; 3 . HbA1c &gt; = 7.0 % &lt; = 10.0 % Visit 1 ( screen ) randomise treatment ; HbA1c &gt; 10.0 % visit 1 ( screen ) openlabel BI 10773 arm ; 4 . Age &gt; = 20 ( Japan ) ; Age &gt; = 18 ( country Japan ) ; 5 . BMI &lt; = 45 kg/m2 Visit 1 ( screen ) ; 6 . Signed date write informed consent date Visit 1 Exclusion criterion : 1 . Uncontrolled hyperglycaemia ; 2 . Acute coronary syndrome ( nonSTEMI , STEMI unstable angina pectoris ) , stroke TIA within 3 month prior inform consent ; 3 . Indication liver disease , either ALT , AST , alkaline phosphatase 3 x ULN ; 4 . Impaired renal function ( eGFR &lt; 50 ml/min ) ; 5 . Bariatric surgery within past two year GI surgery ; 6 . Medical history cancer ; 7 . Contraindications sitagliptin ; 8 . Blood dyscrasia disorder cause haemolysis unstable red blood cell ; 9 . Treatment antidiabetes drug within 12 week prior randomisation ; 10 . Treatment antiobesity drug treatment lead unstable body weight ; 11 . Current treatment systemic steroid change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2DM ; 12 . Premenopausal woman nurse pregnant childbearing potential practicing acceptable method birth control ; 13 . Alcohol drug abuse ; 14 . Intake investigational drug another trial within 30 day prior intake study medication trial ; 15 . Any clinical condition would jeopardize patient safety participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>